Fraxiparine (nadroparin) / Aspen Pharma - LARVOL DELTA

Low dose AAV8-FVIII gene therapy on Chinese severe Hemophilia A patients with sustainable efficacy and safety (ASH 2025) - P=N/A | "An investigator-initiated trial (IIT) (NCT04728841) and a phase Ⅰ/Ⅱ trial (CTR20231730) of GS1191-0445 have beenconducted in Chinese patients with severe Hemophilia A to evaluate long-term efficacy and safety.Nineteen adults with severe Hemophilia A (factor Ⅷ level ≤1%) have been recruited and injected with asingle treatment of AAV8-hFⅧ infusion...Twoimmunosuppressive regimens, prophylactic prednisone or prednisone plus tacrolimus, can be selectedto control the potential AAV capsid immune response from the 7-day prior to study drug infusion to atleast 12 weeks post study drug administration...One of themuses Nadroparin calcium injection and Aspirin enteric-coated tablets to prevent blood clots...Gene therapy with AAV8-hFVIII vector in Chinese patients with Hemophilia A demonstrated a good safetyprofile and sustained, clinically relevant benefit, as measured by a substantial reduction in annualizedrates of bleeding events and complete cessation of prophylactic..."

Clinical • Gene therapy • Cardiovascular • Gene Therapies • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases • Thrombosis

Exploring anti-Xa activity and its correlation with C-Reactive Protein in Intensive Care Unit patients receiving a therapeutic dosage of nadroparin. (PubMed, Thromb Res) - No abstract available

Journal • Critical care • Renal Disease • CRP

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Lung Cancer Receiving Chemotherapy (ASH 2023) - "The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban and apixaban were used in the studies. In our subgroup meta-analysis of POTP with DOACs, there was no statistically significant difference in reduction of VTE in LC patients with Khorana Score ≥2. Hence, the selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from POTP."

Retrospective data • Cardiovascular • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Atypical Presentation of Toxic Shock Syndrome in a Patient With Postpartum Necrotizing Endometritis. (PubMed, Cureus) - "Although she had been prescribed prophylactic nadroparin during pregnancy, anticoagulation was discontinued upon discharge following the cesarean section...Skin lesions gradually stabilized with desquamation and partial healing by day 14. This case highlights an unusual dermatologic manifestation of TSS and underscores the potential contribution of MTHFR C677T/A1298C polymorphisms to thromboinflammatory complications in the postpartum period."

Journal • Acute Kidney Injury • Cardiovascular • Endometriosis • Gynecology • Hematological Disorders • Hypotension • Infectious Disease • Nephrology • Renal Disease • Septic Shock • Thrombosis • MTHFR

A multicenter randomized controlled trial of heparin therapy for patients with functional abnormalities in cardiac mechanical valves (ChiCTR) - P=N/A | N=134 | Recruiting | Sponsor: Northern Theater Command General Hospital of the Chinese People's Liberation Army; Northern Theater Command General Hospital

New trial

Early Massive Left Atrial Thrombosis Following Mitral Bioprosthetic Valve Replacement Due to Suboptimal Anticoagulation: A Case Report. (PubMed, Cureus) - "Anticoagulation therapy was intensified with warfarin and bridged with subcutaneous nadroparin. The thrombus decreased after three weeks and resolved completely by three months, and subsequent echocardiography showed valvular function was satisfactory. This case underscores the importance of strict INR monitoring for high-risk patients, highlighting that warfarin is an effective treatment option for left atrial thrombi following mitral valve replacement."

Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Thrombosis

Gaps and comparison in knowledge and management on venous thromboembolism in nephrotic syndrome: a national survey of pulmonologists and nephrologists (ERS 2025) - "This nationwide study revealed significant disparities in VTE risk perception and implementation of evidence-based guidelines among physicians between pulmonologists and nephrologists."

Cardiovascular • Glomerulonephritis • Nephrology • Renal Disease • Venous Thromboembolism

Intracranial Hemorrhage With Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin in Brain Tumors: A Review and Meta-Analysis. (PubMed, Neurology) - "In the current meta-analysis, DOACs were associated with significantly lower ICH risk than LMWH in patients with anticoagulated brain tumor, particularly those with primary brain tumors. Findings support DOACs as a safe anticoagulant in arterial and venous thromboembolism. Given observational designs with inherent confounding, findings warrant cautious interpretation."

Journal • Retrospective data • Brain Cancer • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Oncology • Solid Tumor • Venous Thromboembolism

Efficacy and safety study of tranexamic acid combined with low-molecular-weight heparin and nadroparin calcium in postoperative application after joint replacement: a retrospective cohort study. (PubMed, BMC Musculoskelet Disord) - "This study found that the clinical efficacy and safety of the TXA + Nadroparine and TXA + LMWH groups were basically the same after joint replacement surgery. However, the TXA + LMWH group demonstrated better prevention of thrombosis and significantly lower overall hospitalization costs compared to the TXA + Nadroparine group."

Clinical • Journal • Retrospective data • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Oncology • Orthopedics • Osteoarthritis • Pain • Pulmonary Embolism • Respiratory Diseases • Rheumatology • Thrombosis • CXCL8 • IL6 • TNFA

Improving outcome in SubaraChnoid HEMorrhage wIth nAdroparin (ISCHEMIA): a prospective randomised controlled trial protocol. (PubMed, BMJ Open) - P2 | "The study results will be submitted for publication in peer-reviewed journals and presented at international conferences. NCT04507178."

Clinical protocol • Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Subarachnoid Hemorrhage

Effectiveness of rivaroxaban (Riqulatron) for prevention of venous thromboembolic complications in total knee replacement (PubMed, Khirurgiia (Mosk)) - "Despite similar clinical efficacy, Riqulatron demonstrated more obvious pharmacoeconomic effect compared to multimodal scheme."

Journal • Cardiovascular • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Thrombosis

Analysis of the safety and effectiveness of antithrombotic prophylaxis after elective total knee and hip arthroplasty: a prospective single-center real-world study (PubMed, Ter Arkh) - "In a cohort of real-world patients undergoing elective TKA or THA, the differences between the effectiveness and safety of various anticoagulant prophylaxis regimens were not statistically significant. The incidence of thrombosis was low, and these complications were mainly reported in non-compliant patients. The incidence of bleeding in patients taking anticoagulants with antiplatelet agents was not elevated, however, the size of this subpopulation is small and does not allow to perform a significant assessment of the safety of this treatment regimen. Based on the findings, it is reasonable to develop additional methods to improve patient compliance in order to reduce the frequency of medication errors and decrease the incidence of possible complications."

Journal • Observational data • Real-world evidence • Cardiovascular • Gastroenterology • Hematological Disorders • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology • Thrombosis

Whether an optimal strategy exists for VTE prevention in critically ill patients: Insights from guidelines and randomized controlled trials. (PubMed, Eur J Intern Med) - "Although the 17 CPGs propose various strategies for VTE prevention, substantial differences exist in their quality and clinical applicability. Existing clinical evidence fails to demonstrate superior prophylactic efficacy among VTE prevention strategies in critically ill patients."

Journal • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Bleeding Events and Correlation with Anti-Xa Levels and Therapeutic Nadroparin Dose in Patients with Impaired Renal Function. (PubMed, Semin Thromb Hemost) - "However, a correlation was found between the dose and the occurrence of a bleeding event. Therefore, it is questionable whether the focus on monitoring anti-Xa levels is a justified method to reduce the risk of a bleeding event."

Journal • Nephrology • Renal Disease

Effects of low molecular weight heparin in advanced chronic kidney diseases (ISTH 2025) - "In patients receiving nadroparin for prophylaxis of DVT, 43.3% reached the target anti-Xa levels, while 33.3% had anti-Xa levels below this range and 23.4% were over-anticoagulated. Table or Figure Upload"

Metastases • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease • Thrombosis

A randomized controlled study of heparin versus low molecular weight heparin in preventing catheter-related thrombosis in neonates after congenital heart disease surgery (ChiCTR) - P=N/A | N=100 | Recruiting | Sponsor: Fujian Children's Hospital; Fujian Children’s Hospital

New trial • Cardiovascular • Heart Failure • Hematological Disorders • Thrombosis

Heparins Enhance C1 Esterase Inhibitor Activity: A Promising Remedy for Acute Hereditary Angioedema (ATS 2025) - "Our goal is to determine if unfractionated heparin and two low-molecular weight heparins (enoxaparin and nadroparin) can augment C1-INH activity ex vivo in the sera of patients with HAE and in an in vitro biochemical assay. low-molecular weight heparin augments C1-INH activity and should be studied as a potential treatment for acute HAE."

Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Reduced Anticoagulation Targets in ECLS (RATE) (clinicaltrials.gov) - P3 | N=330 | Completed | Sponsor: University Medical Center Groningen | Recruiting ➔ Completed | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2023 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Hematological Disorders • Respiratory Diseases • Thrombosis

Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. (PubMed, Br J Clin Pharmacol) - "Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible."

Journal

Prevention of venous thromboembolic complications in patients with ulcerative colitis (PubMed, Ter Arkh) - "Our results demonstrate that primary prevention with an LMWH significantly reduces the risk of VTEC in patients with UC hospitalized in a round-the-clock hospital."

Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Respiratory Diseases • Ulcerative Colitis

Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients? (PubMed, Anaesthesiol Intensive Ther) - "UFH anticoagulation may provide better flow optimization in the oxygenator, but the risk of life-threatening bleeding may increase. The present findings need to be fully elucidated in prospective studies on a larger critically ill population supported with respiratory ECMO."

Clinical • Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease

Trousseau Syndrome-Associated Acute Multifocal Cerebral Infarction: When Triple-Pathway Antithrombotic Therapy Overcomes Low Molecular Weight Heparin Resistance. (PubMed, Cureus) - "The initial infusion of nadroparin, which was co-administered with aspirin, achieved almost no anticoagulation. Consequently, the strategy was escalated to triple-pathway antithrombotic therapy through substitution with argatroban, clopidogrel, and cilostazol. This regimen successfully prevented further thrombotic complications. This case provides rare documentation of catastrophic cerebral parenchymal involvement secondary to TS. Furthermore, the effective application of anticoagulation-antiplatelet combination therapy following low-molecular-weight heparin (LMWH) resistance offers a potential management paradigm for refractory hypercoagulable states."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis

Low-molecular-weight heparins utilization in pregnant and postpartum women: a real-world analysis in China (2016-2021). (PubMed, Front Pharmacol) - "In terms of DDC, low-molecular-weight heparin sodium, dalteparin sodium, and enoxaparin sodium were the lowest. Enoxaparin sodium, nadroparin calcium, and low-molecular-weight heparin calcium were the most common LMWH. Advanced age (>35 years old), cesarean section, diabetes, miscarriage, and preterm birth were the most common pregnancy-related VTE risk factors linked to LMWH prescription."

Journal • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Venous Thromboembolism

PORTAL VEIN TROMBOSIS IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS (APASL 2025) - "Case description Patient A.S., female, 65 years old, with HCV-associated cirrhosis, Child-Pugh C, twice treated (null-responders on the treatment with PEG-IFNa-2a plus Ribavirin in 2005 and SVR 12 on treatment with Sofosbuvir/Ledipasvir in 2016), portal hypertension, severe thrombocytopenia, obesity, diabetes mellitus, cholecystolithiasis...Nadroparin and Apixaban started by hematologist, but due to hemorrhagic syndrome on 4 days of Apixaban therapy was stopped by the patient... Management of difficult-to-treat patient with decompensated liver cirrhosis complicated by portal vein thrombosis till now is one of major problems in hepatology. Bacterial infections often a predisposing factor for pylethrombosis development in cirrhotic liver. Careful monitoring with experienced hepatologists and multidisciplinary approach is crucial."

Clinical • Cardiovascular • CNS Disorders • Diabetes • Fibrosis • Gastroenterology • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Portal Hypertension • Rare Diseases • Thrombocytopenia • Thrombosis • Urology

TIPOTEE: Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events (clinicaltrials.gov) - P=N/A | N=280 | Completed | Sponsor: Leiden University Medical Center | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Sep 2024

Trial completion • Trial completion date • Cardiovascular • Hematological Disorders • Thrombosis